{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:57:29Z","timestamp":1773280649212,"version":"3.50.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1097\/iae.0b013e318285c99d","type":"journal-article","created":{"date-parts":[[2013,3,28]],"date-time":"2013-03-28T14:25:34Z","timestamp":1364480734000},"page":"1623-1629","source":"Crossref","is-referenced-by-count":22,"title":["REPEATED INTRAVITREAL BEVACIZUMAB INJECTION WITH AND WITHOUT MACULAR GRID PHOTOCOAGULATION FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"33","author":[{"given":"Kamal A. M.","family":"Solaiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad M.","family":"Diab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif A.","family":"Dabour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210130","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic.","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"},{"key":"R2-18-20210130","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","article-title":". The Wisconsin Epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.","volume":"91","author":"Klein","year":"1984","journal-title":"Ophthalmology"},{"key":"R3-18-20210130","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0161-6420(89)32699-6","article-title":". The Wisconsin Epidemiologic study of diabetic retinopathy. XI. The incidence of macular edema.","volume":"96","author":"Klein","year":"1989","journal-title":"Ophthalmology"},{"key":"R4-18-20210130","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","article-title":"Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies.","volume":"26","author":"Ciulla","year":"2003","journal-title":"Diabetes Care"},{"key":"R5-18-20210130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/08820539909069541","article-title":"The pathogenesis of edema in diabetic maculopathy.","volume":"14","author":"Antcliff","year":"1999","journal-title":"Semin Ophthalmol"},{"key":"R6-18-20210130","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/IAE.0b013e318159e7d2","article-title":"Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema.","volume":"28","author":"Figueroa","year":"2008","journal-title":"Retina"},{"key":"R7-18-20210130","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0161-6420(91)32082-7","article-title":"Modified grid laser photocoagulation for diffuse macular edema. Long term visual results.","volume":"98","author":"Lee","year":"1991","journal-title":"Ophthalmology"},{"key":"R8-18-20210130","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0161-6420(86)33638-8","article-title":"Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema.","volume":"93","author":"Olk","year":"1986","journal-title":"Ophthalmology"},{"key":"R9-18-20210130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00006982-198500520-00001","article-title":"Grid photocoagulation for diffuse macular edema.","volume":"5","author":"McDonald","year":"1985","journal-title":"Retina"},{"key":"R10-18-20210130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1023\/A:1002499920673","article-title":"When and how to do a grid laser for diabetic macular edema.","volume":"97","author":"Bandello","year":"1999","journal-title":"Doc Ophthalmol"},{"key":"R11-18-20210130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00006982-200601000-00002","article-title":". Pars plana vitrectomy with and without peeling of the inner limiting membrane for diabetic macular edema.","volume":"26","author":"Patel","year":"2006","journal-title":"Retina"},{"key":"R12-18-20210130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00006982-200602000-00003","article-title":". Evaluating adjunctive surgical procedures during vitrectomy for diabetic macular edema.","volume":"26","author":"Mochizuki","year":"2006","journal-title":"Retina"},{"key":"R13-18-20210130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress.","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"R14-18-20210130","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ophtha.2004.11.045","article-title":". Vitreous levels of vascular endothelial growth factor and intracellular adhesion molecule 1 are related to diabetic macular edema.","volume":"112","author":"Funatsu","year":"2005","journal-title":"Ophthalmology"},{"key":"R15-18-20210130","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","article-title":". Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.","volume":"26","author":"Haritoglou","year":"2006","journal-title":"Retina"},{"key":"R16-18-20210130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","article-title":". Primary intravitreal bevacizumab (Avastin) for diabetic macular edema.","volume":"114","author":"Arevalo","year":"2007","journal-title":"Ophthalmology"},{"key":"R17-18-20210130","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0b013e31815ec261","article-title":". Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.","volume":"27","author":"Soheilian","year":"2007","journal-title":"Retina"},{"key":"R18-18-20210130","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/IAE.0b013e3181e1ed07","article-title":"Intravitreal bevacizumab andor macular grid photocoagulation as a primary treatment for diffuse diabetic macular edema.","volume":"30","author":"Solaiman","year":"2010","journal-title":"Retina"},{"key":"R19-18-20210130","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ajo.2007.12.031","article-title":". Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.","volume":"145","author":"Shimura","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R20-18-20210130","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3928\/1542-8877-20000701-07","article-title":"Combined macular grid and combined panretinal photocoagulation for diffuse diabetic macular edema and proliferative diabetic retinopathy.","volume":"31","author":"Lee","year":"2000","journal-title":"Ophthalmic Surg Lasers"},{"key":"R21-18-20210130","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin).","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"key":"R22-18-20210130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/IAE.0b013e3181619bee","article-title":". Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.","volume":"28","author":"Wu","year":"2008","journal-title":"Retina"},{"key":"R23-18-20210130","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/IAE.0b013e3181bcef53","article-title":". Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions. Results from the Pan-American Collaborative Retina Study Group at 24 months.","volume":"29","author":"Wu","year":"2009","journal-title":"Retina"},{"key":"R24-18-20210130","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/IAE.0b013e3181853d2a","article-title":"Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema.","volume":"28","author":"Roh","year":"2008","journal-title":"Retina"},{"key":"R25-18-20210130","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":". Two- year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study.","volume":"117","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"key":"R26-18-20210130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/archopht.1984.01040030104047","article-title":"Repair of the pigment epithelial barrier following photocoagulation.","volume":"102","author":"Wallow","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R27-18-20210130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/IAE.0b013e3181a3b8e7","article-title":". Bevacizumab in macular edema. Functional and anatomic changes in a prospective case series.","volume":"29","author":"Forte","year":"2009","journal-title":"Retina"},{"key":"R28-18-20210130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ophtha.2006.06.052","article-title":"Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema.","volume":"114","year":"2007","journal-title":"Ophthalmology"},{"key":"R29-18-20210130","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":". A prospective radomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study). 12-month data: Reort 2.","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"key":"R30-18-20210130","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/bies.20092","article-title":"VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection.","volume":"26","author":"Storkebaum","year":"2004","journal-title":"Bioassays"},{"key":"R31-18-20210130","doi-asserted-by":"crossref","first-page":"12439","DOI":"10.1523\/JNEUROSCI.0434-06.2006","article-title":". Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-12 and Akt pathways.","volume":"26","author":"Kilic","year":"2006","journal-title":"J Neurosci"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0b013e318285c99d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T16:31:12Z","timestamp":1644683472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201309000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e318285c99d","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}